409 related articles for article (PubMed ID: 36551630)
21. Targeting immune checkpoints in anti-neutrophil cytoplasmic antibodies associated vasculitis: the potential therapeutic targets in the future.
Pan M; Zhao H; Jin R; Leung PSC; Shuai Z
Front Immunol; 2023; 14():1156212. PubMed ID: 37090741
[TBL] [Abstract][Full Text] [Related]
22. Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party.
Lu C; Tan Y
Mol Ther Oncol; 2024 Mar; 32(1):200773. PubMed ID: 38596295
[TBL] [Abstract][Full Text] [Related]
23. The implication of anti-PD-1 therapy in cancer patients for the vaccination against viral and other infectious diseases.
Retnakumar SV; Chauvin C; Bayry J
Pharmacol Ther; 2023 May; 245():108399. PubMed ID: 37001736
[TBL] [Abstract][Full Text] [Related]
24. Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy.
Torphy RJ; Schulick RD; Zhu Y
Int J Mol Sci; 2017 Dec; 18(12):. PubMed ID: 29211042
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy.
Li F; Chen Y; Pang M; Yang P; Jing H
Clin Exp Immunol; 2021 Jul; 205(1):1-11. PubMed ID: 33675535
[TBL] [Abstract][Full Text] [Related]
26. Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review.
Li YQ; Chen XM; Si GF; Yuan XM
Biomol Biomed; 2024 Apr; ():. PubMed ID: 38581716
[TBL] [Abstract][Full Text] [Related]
27. Targeting TIGIT for Immunotherapy of Cancer: Update on Clinical Development.
Rotte A; Sahasranaman S; Budha N
Biomedicines; 2021 Sep; 9(9):. PubMed ID: 34572463
[TBL] [Abstract][Full Text] [Related]
28. Traditional Treatment Approaches and Role of Immunotherapy in Lung Malignancy and Mesothelioma.
Tamanna MT; Egbune C
Cancer Treat Res; 2023; 185():79-89. PubMed ID: 37306905
[TBL] [Abstract][Full Text] [Related]
29. Immune Checkpoints, Inhibitors and Radionuclides in Prostate Cancer: Promising Combinatorial Therapy Approach.
Kgatle MM; Boshomane TMG; Lawal IO; Mokoala KMG; Mokgoro NP; Lourens N; Kairemo K; Zeevaart JR; Vorster M; Sathekge MM
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33921181
[TBL] [Abstract][Full Text] [Related]
30. Targeting novel inhibitory receptors in cancer immunotherapy.
Ding QQ; Chauvin JM; Zarour HM
Semin Immunol; 2020 Jun; 49():101436. PubMed ID: 33288379
[TBL] [Abstract][Full Text] [Related]
31. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
32. Emerging immunotherapy targets in lung cancer.
Zhu HH; Feng Y; Hu XS
Chin Med J (Engl); 2020 Oct; 133(20):2456-2465. PubMed ID: 32947361
[TBL] [Abstract][Full Text] [Related]
33. New Clinical Approaches and Emerging Evidence on Immune-Checkpoint Inhibitors as Anti-Cancer Therapeutics: CTLA-4 and PD-1 Pathways and Beyond.
Christodoulou MI; Zaravinos A
Crit Rev Immunol; 2019; 39(5):379-408. PubMed ID: 32422018
[TBL] [Abstract][Full Text] [Related]
34. The Features of Checkpoint Receptor-Ligand Interaction in Cancer and the Therapeutic Effectiveness of Their Inhibition.
Kuzevanova A; Apanovich N; Mansorunov D; Korotaeva A; Karpukhin A
Biomedicines; 2022 Aug; 10(9):. PubMed ID: 36140182
[TBL] [Abstract][Full Text] [Related]
35. Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC).
Chae YK; Arya A; Iams W; Cruz MR; Chandra S; Choi J; Giles F
J Immunother Cancer; 2018 May; 6(1):39. PubMed ID: 29769148
[TBL] [Abstract][Full Text] [Related]
36. Tumor immune checkpoints and their associated inhibitors.
Gao Z; Ling X; Shi C; Wang Y; Lin A
J Zhejiang Univ Sci B; 2022 Oct; 23(10):823-843. PubMed ID: 36226537
[TBL] [Abstract][Full Text] [Related]
37. Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
Scutti JAB
Int J Oncol; 2018 Apr; 52(4):1041-1056. PubMed ID: 29484440
[TBL] [Abstract][Full Text] [Related]
38. Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma.
Mei Z; Huang J; Qiao B; Lam AK
Int J Oral Sci; 2020 May; 12(1):16. PubMed ID: 32461587
[TBL] [Abstract][Full Text] [Related]
39. Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses.
Chen X; Pan X; Zhang W; Guo H; Cheng S; He Q; Yang B; Ding L
Acta Pharm Sin B; 2020 May; 10(5):723-733. PubMed ID: 32528824
[TBL] [Abstract][Full Text] [Related]
40. Immunotherapy Based on Immune Checkpoint Molecules and Immune Checkpoint Inhibitors in Gastric Cancer-Narrative Review.
Poniewierska-Baran A; Sobolak K; Niedźwiedzka-Rystwej P; Plewa P; Pawlik A
Int J Mol Sci; 2024 Jun; 25(12):. PubMed ID: 38928174
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]